AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$GRAL

Ofman Joshua J. sold $425K of GRAL

Ofman Joshua J. (Chief Executive Officer) sold 5,000 shares of GRAIL, Inc. (GRAL) at $85.02 ($0.43M total) on 2026-08-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ofman Joshua J.
Published Sep 1, 2026, 12:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 12:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GRAL
Neutral
high confidence
Mentioned
$GRAL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRALNeutralLow
01

Why it matters

The transaction modestly reduces insider ownership but does not signal new information about GRAIL's operations or outlook.

02

Market read

Low relevance; routine insider sale with limited market impact.

03

What to watch

The sale is pre-arranged under a 10b5-1 plan, indicating no discretionary motive.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-31

Background

Form 4 filings disclose insider transactions; routine sales are common and often pre-planned.

Company-level read

Ticker impact

$GRALNeutralHigh confidence
Context

CEO Joshua Ofman sold 5,000 shares for $425K via a 10b5-1 plan, reducing his stake to 397,271 shares.

Expected impact

Minimal impact; price likely unchanged.

Evidence & confidence

Sale size is modest relative to total shares outstanding; market typically views routine insider sales as low significance.

Market effects

Sector

No sector-wide implications; GRAIL operates in biotech diagnostics.

Regional

Limited to US market; no regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

If investors interpret any insider selling as a negative signal, they may short the stock.

Key entities

  • Company
    GRAIL, Inc.

    US-listed biotech firm (ticker GRAL).

  • Executive
    Joshua J. Ofman

    Chief Executive Officer of GRAIL.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GRAL insider trading history →

Related articles

OCT 3
$GRALHighAI 8/10

Why GRAIL (GRAL) Is Up 8.1% And What's Next After Galleri FDA Backing

GRAIL (GRAL) shares rose 8.1% after an FDA advisory panel backed its Galleri blood test, citing strong clinical data. The test showed 99.64% specificity and 60.3% positive predictive value in detecting early-stage cancers. The company projects $348.4M revenue and $60.1M earnings by 2029, but analysts warn of reimbursement risks and high cash burn.

simplywall.st3 min
SEP 30
$GRALHighAI 8/10

Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.

Grail's (GRAL) stock rose after an FDA advisory committee voted favorably on its Galleri test. The test, already available, needs insurer coverage for growth. FDA approval, likely following the vote, could prompt insurer evaluation. Insurers will assess cost-effectiveness and clinical utility. Grail's data shows Galleri's potential in detecting 12 deadly cancers.

aol.com2 min
SEP 30
$IOVAMedAI 8/10

Biotech Stocks At 52-Week Highs - IOVA +31%, XERS, GRAL, ABCL, SGHT

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.

rttnews.com2 min